|Bid||33.70 x 100|
|Ask||34.63 x 100|
|Day's Range||33.92 - 34.48|
|52 Week Range||29.83 - 37.39|
|PE Ratio (TTM)||28.67|
|Dividend & Yield||1.28 (3.78%)|
|1y Target Est||N/A|
A European Medicines Agency panel recommended on Friday approving Novartis's Kisqali drug, bolstering the Swiss drugmaker's bid to challenge rival Pfizer's Ibrance against tough-to-treat breast cancer. ...
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Pfizer Inc. a score of 50. Our analysis is based on comparing Pfizer Inc. with the following peers – Merck & Co., Inc., Johnson & Johnson, Bristol-Myers Squibb Company, Eli Lilly and Company, Novartis AG Sponsored ADR, GlaxoSmithKline plc Sponsored ADR, Amgen Inc., Mylan N.V., Abbott Laboratories ... Read more (Read more...)
A new analyst took over coverage and released a note to investors.